Lantern Pharma Announces Publication In Clinical Cancer Research Highlighting The Enhanced Efficacy Of LP-184 In Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma Inc. (NASDAQ:LTRN) has announced the publication of in vivo data highlighting the enhanced efficacy of its drug candidate LP-184 in glioblastoma (GBM) in Clinical Cancer Research. LP-184 is a unique small molecule that exploits common vulnerabilities in solid tumor and CNS cancers with DNA damage repair (DDR) deficiencies. A Phase 1 clinical trial evaluating LP-184 in patients with advanced solid tumors is underway, with completion expected in the first half of 2024. Lantern estimates that LP-184 has a global aggregate market potential of approximately $11-13 billion.
October 03, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantern Pharma's drug candidate LP-184 has shown enhanced efficacy in glioblastoma, with a Phase 1 clinical trial currently underway. The company estimates a potential market of $11-13 billion for LP-184.
The news of the publication of in vivo data showing the enhanced efficacy of Lantern Pharma's drug candidate LP-184 in glioblastoma is positive for the company. The ongoing Phase 1 clinical trial and the estimated market potential of $11-13 billion for LP-184 further increase the relevance and importance of this news for Lantern Pharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100